Viktor Drvota

Chief Executive Officer & Chief Investment Officer at Karolinska Development AB

Viktor Drvota

Viktor Drvota

Chief Executive Officer & Chief Investment Officer at Karolinska Development AB

Career Highlights

Karolinska Development AB
Karolinska Development AB (Private Equity)

RelSci Relationships


Number of Boards






Contact Data
Trying to get in touch with Viktor Drvota? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
RelSci Relationships are individuals Viktor Drvota likely has professional access to. A relationship does not necessarily indicate a personal connection.

Senior Advisor at Industrifonden

Relationship likelihood: Strong

Former Deputy Chief Executive Officer at Karolinska Development AB (Private Equity)

Relationship likelihood: Strong

Former Vice President, Clinical Development at Karolinska Development AB

Relationship likelihood: Strong

Procurator at KTH Chalmers Capital KB

Relationship likelihood: Strong

Investment Manager at Industrifonden

Relationship likelihood: Strong

Senior Scientist at Johnson & Johnson

Relationship likelihood: Strong

Partner at HealthCap AB

Relationship likelihood: Strong

Former Executive Vice President at Capio AB

Relationship likelihood: Strong

Chief Executive Officer & Director at Rolfsen Consulting AB

Relationship likelihood: Strong

Senior Advisor at Lipidor AB

Relationship likelihood: Strong

Paths to Viktor Drvota
Potential Connections via
Relationship Science
Viktor Drvota
Chief Executive Officer & Chief Investment Officer at Karolinska Development AB
Ph.D. Unknown

Karolinska Institutet is a medical university in Solna within the Stockholm urban area, Sweden, and one of Europe's largest and most prestigious medical universities. It was founded in 1810 on Kungsholmen on the west side of Stockholm; the main campus was relocated decades later to Solna, just outside Stockholm. A second campus was established more recently in Flemingsberg, Huddinge, south of Stockholm.

Career History
Chief Executive Officer & Chief Investment Officer
2015 - Current

Karolinska Development AB engages in the investment in pharmaceutical business. It focuses on identifying medical innovations and investing in the creation and growth of companies that develop these assets into differentiated products that will make a difference to patient's lives. The company was founded in 2006 and is headquartered in Solna, Sweden.

Chief Executive Officer
2016 - 2017

KD's investment approach aims to transfer life sciences innovations into commercial applications while improving human health. They are an early investor with the objective of being the lead investor. They generally maintain a significant position in their portfolio firms until exit. They endeavor to rapidly build value in high risk opportunities.Among key investment criteria, they seek innovations, either pharmaceutical or medical technology applications, which address unmet medical needs. KD looks for opportunities displaying a strong IP position, preferably with a patent application, as well as unique skills or processes.KD works closely with regional Nordic academic and research institutions. Their deal flow agreement with Karolinska Institutet Innovations ensures priority access of promising opportunities at a very early stage. In addition to capital infusion, the firm supports their investments through business development expertise, technical specialists and access to their wide-ranging professional network.

Head-Investment Area Life Science
2002 - 2016

SEB VC is an active, long-term manager which makes venture capital investments in growth companies in the technology, life science and industrial sectors, aiming to add competence and provide a network for investee companies. The firm focuses on companies which have a unique product or service with a sustainable competitive edge, a highly skilled management team who are also partners in the company and a business concept with international market potential.SEB VC takes a minority position in their investee companies, seeking board representation and making investments up to SEK 80 million.

Boards & Committees
2016 - Current

OssDsign AB designs and manufactures implants and material technology for bone replacement. It is an orthopedic medical device company that develops implantable products. It develops pioneering implants for bone healing with focus on cranial surgery. The firm's product OssDsign Cranio PSI is an implant for skull reconstruction. It uses new design solutions, material compositions, and manufacturing processes mainly based on proprietary bioceramic technologies. The company was by Håkan Gunnar Engqvist, Carl Thomas Engstrand, Bo Erik Qwarnstrom, and Jonas Åberg in May 2011 and is headquartered in Uppsala, Sweden.


Part of InDex Pharmaceuticals Holding AB, InDex Diagnostics AB is a Swedish company located in Solna that manufactures pharmaceutical products. Peter Hakim Zerhouni has been the CEO since 2015.

Member, Board of Directors

Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Viktor Drvota. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Viktor Drvota's profile does not indicate a business or promotional relationship of any kind between RelSci and Viktor Drvota.
  • be_ixf; php_sdk; php_sdk_1.4.15